Good and rapid answers.
But I'm not convinced that Tom answered this.
Our orphan drug designations prevent AZ or any pharma from actively marketing Exenatide for IIH.
But what prevents a doctor from prescribing Byetta or Bydureon off-label for IIH? Doctors prescribe off-label all the time.
Is it just the fact that those drugs cost USD 500 per month and insurance won't pay for off-label use? So the only patients who would ask for Byetta and Bydureon are uninsured patients?
Good and rapid answers.But I'm not convinced that Tom...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.839M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 41290 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 9000 | 1 |
View Market Depth
| Last trade - 16.21pm 04/07/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable